氯氮平辅助利培酮治疗难治性精神分裂症患者的疗效及安全性
|
摘要
目的探析氯氮平辅助利培酮用于治疗难治性精神分裂症患者的疗效及安全性。方法 78例难治性精神分裂症患者,通过随机号码表法分为普通组与辅助组,各39例。普通组采用利培酮单独药物治疗,辅助组采用氯氮平辅助利培酮治疗。对两组患者治疗前及治疗3、6、9、12周后的阳性和阴性症状量表(PANSS)评分总分,临床治疗效果及不良反应发生情况等进行比较。结果治疗前,两组PANSS评分总分比较差异无统计学意义(P>0.05);治疗3、6、9、12周后,两组PANSS评分总分均明显低于治疗前,且辅助组PANSS评分总分均明显低于普通组,差异具有统计学意义(P<0.05)。普通组患者总有效率为69.23%,明显低于辅助组的89.74%,差异具有统计学意义(P<0.05)。普通组患者不良反应发生率25.64%与辅助组的23.08%比较差异无统计学意义(P>0.05)。结论针对难治性精神分裂症患者,使用氯氮平辅助利培酮进行治疗,可以在控制患者不良反应发生率的同时,提高临床治疗效果,是为更好的临床治疗方案。
Objective To discuss and analyze the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia patients. Methods A total of 78 refractory schizophrenia patients were divided by random number table into common group and auxiliary group, with 39 cases in each group. Common group was treated with risperidone only, and auxiliary group was treated with clozapine combined with risperidone. Comparison were made on clinical treatment effect and occurrence of adverse reactions between the two groups. Results Before treatment, both groups had no positive and negative symptom scale(PANSS) score before and after 3, 6, 9 and 12 weeks, statistically significant difference in total score of PANSS score(P>0.05). After 3, 6, 9 and 12 weeks of treatment, both groups had obviously lower total PANSS score than before treatment, and auxiliary group had obviously lower total PANSS score than common group. Their difference was statistically significant(P<0.05). Common group had obviously lower total effective rate as 69.23% than 89.74% in auxiliary group, and the difference was statistically significant(P<0.05). Common group had no statistically significant difference in incidence of adverse reactions as 25.64%, comparing with 23.08% in auxiliary group(P>0.05). Conclusion Application of clozapine and risperidone for patients with refractory schizophrenia can improve the clinical treatment effect while controlling the incidence of adverse reactions. It is a better clinical treatment regimen.
Objective To discuss and analyze the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia patients. Methods A total of 78 refractory schizophrenia patients were divided by random number table into common group and auxiliary group, with 39 cases in each group. Common group was treated with risperidone only, and auxiliary group was treated with clozapine combined with risperidone. Comparison were made on clinical treatment effect and occurrence of adverse reactions between the two groups. Results Before treatment, both groups had no positive and negative symptom scale(PANSS) score before and after 3, 6, 9 and 12 weeks, statistically significant difference in total score of PANSS score(P>0.05). After 3, 6, 9 and 12 weeks of treatment, both groups had obviously lower total PANSS score than before treatment, and auxiliary group had obviously lower total PANSS score than common group. Their difference was statistically significant(P<0.05). Common group had obviously lower total effective rate as 69.23% than 89.74% in auxiliary group, and the difference was statistically significant(P<0.05). Common group had no statistically significant difference in incidence of adverse reactions as 25.64%, comparing with 23.08% in auxiliary group(P>0.05). Conclusion Application of clozapine and risperidone for patients with refractory schizophrenia can improve the clinical treatment effect while controlling the incidence of adverse reactions. It is a better clinical treatment regimen.
引文
[1]杨海燕,刘学文.氯氮平辅助利培酮治疗难治性精神分裂症患者的效果观察.中国民康医学,2016,28(17):9-11.
[2]王文政,蒲城城,蒋江灵,等.抗精神病药物合并电抽搐治疗对难治性精神分裂症患者的疗效和安全性:一项系统综述和meta分析(英文).上海精神医学,2015(4):206-219.
[3]张丹.中药联合氯氮平、舒必利治疗难治性精神分裂症的效果观察.临床合理用药杂志,2017,10(20):9-10.
[4]陈丽波,陈仙萍,郑梦甜.氯氮平治疗和康复护理对精神分裂症患者社会功能缺陷的效果.中国生化药物杂志,2017,37(10):338-339.
[5]杨崇添,黄永倩,黄秀敏.利培酮合并氯氮平治疗难治性精神分裂症临床研究.黑龙江医药,2017(5):1047-1049.
[6]李媛媛,张云淑,王红英,等.氯氮平片联合利培酮片治疗难治性精神分裂症安全性的系统评价.中国临床药理学杂志,2017,33(18):1813-1816.
[7]李静,袁捷,周雪丽,等.氨磺必利与氯氮平治疗阴性症状为主的精神分裂症的疗效及安全性比较.药物评价研究,2017,40(5):691-695.
[8]杨相国,谢道伟.氯氮平治疗难治性精神分裂症的疗效观察.中国医院用药评价与分析,2017,17(10):1339-1340.
[9]耿艳萍,姜琳.利培酮和氯氮平治疗儿童精神分裂症患儿不良反应对比及护理要点分析.中国现代药物应用,2017,11(3):171-172.
[10]卢宝,梁月竹,王春钢,等.心理治疗联合利培酮治疗精神分裂症的疗效及安全性.现代生物医学进展,2017,17(12):2357-2360.
[11]李家凤.分析利培酮与氯氮平联合治疗精神分裂症的疗效.北方药学,2017,14(5):131.
[12]李江舸.利培酮与氯氮平对精神分裂症患者阴性症状改善的对照研究.慢性病学杂志,2017(4):371-373.
[13]曾义芝,吴林玲.利培酮和奥氮平在难治性精神分裂症患者治疗中的应用效果观察.医药前沿,2017,7(24):126.
[14]吴帅波.分析阿立哌唑、利培酮、氯氮平对精神分裂症的治疗效果及对机体糖脂代谢的的影响.心理医生,2017,23(2):167-168.
[15]朱德超.比较利培酮与氯氮平对男性首发精神分裂症患者认知功能及社会功能的影响.中国药物经济学,2017,12(8):77-79.
[2]王文政,蒲城城,蒋江灵,等.抗精神病药物合并电抽搐治疗对难治性精神分裂症患者的疗效和安全性:一项系统综述和meta分析(英文).上海精神医学,2015(4):206-219.
[3]张丹.中药联合氯氮平、舒必利治疗难治性精神分裂症的效果观察.临床合理用药杂志,2017,10(20):9-10.
[4]陈丽波,陈仙萍,郑梦甜.氯氮平治疗和康复护理对精神分裂症患者社会功能缺陷的效果.中国生化药物杂志,2017,37(10):338-339.
[5]杨崇添,黄永倩,黄秀敏.利培酮合并氯氮平治疗难治性精神分裂症临床研究.黑龙江医药,2017(5):1047-1049.
[6]李媛媛,张云淑,王红英,等.氯氮平片联合利培酮片治疗难治性精神分裂症安全性的系统评价.中国临床药理学杂志,2017,33(18):1813-1816.
[7]李静,袁捷,周雪丽,等.氨磺必利与氯氮平治疗阴性症状为主的精神分裂症的疗效及安全性比较.药物评价研究,2017,40(5):691-695.
[8]杨相国,谢道伟.氯氮平治疗难治性精神分裂症的疗效观察.中国医院用药评价与分析,2017,17(10):1339-1340.
[9]耿艳萍,姜琳.利培酮和氯氮平治疗儿童精神分裂症患儿不良反应对比及护理要点分析.中国现代药物应用,2017,11(3):171-172.
[10]卢宝,梁月竹,王春钢,等.心理治疗联合利培酮治疗精神分裂症的疗效及安全性.现代生物医学进展,2017,17(12):2357-2360.
[11]李家凤.分析利培酮与氯氮平联合治疗精神分裂症的疗效.北方药学,2017,14(5):131.
[12]李江舸.利培酮与氯氮平对精神分裂症患者阴性症状改善的对照研究.慢性病学杂志,2017(4):371-373.
[13]曾义芝,吴林玲.利培酮和奥氮平在难治性精神分裂症患者治疗中的应用效果观察.医药前沿,2017,7(24):126.
[14]吴帅波.分析阿立哌唑、利培酮、氯氮平对精神分裂症的治疗效果及对机体糖脂代谢的的影响.心理医生,2017,23(2):167-168.
[15]朱德超.比较利培酮与氯氮平对男性首发精神分裂症患者认知功能及社会功能的影响.中国药物经济学,2017,12(8):77-79.